48
Participants
Start Date
August 15, 2024
Primary Completion Date
February 28, 2027
Study Completion Date
February 28, 2027
LY3954068
Administered IT
Placebo
Administered IT
Flortaucipir F18
Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan
NOT_YET_RECRUITING
Duke University, Durham
RECRUITING
CenExel iResearch, LLC (CenExel iRA), Decatur
RECRUITING
Charter Research, LLC, The Villages
RECRUITING
K2 Medical Research, LLC, Maitland
NOT_YET_RECRUITING
Massachusetts General Hospital (MGH), Charlestown
RECRUITING
CenExel AMRI, Toms River
RECRUITING
The University of Tokyo Hospital, Bunkyō City
NOT_YET_RECRUITING
National Hospital for Neurology and Neurosurgery (UCLH), London
NOT_YET_RECRUITING
Royal Hallamshire Hospital, Sheffield
NOT_YET_RECRUITING
University Hospital Southampton, Southampton
Eli Lilly and Company
INDUSTRY